SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc. (Nasdaq:XNPT) announced today that David A. Stamler, M.D., has joined the company as senior vice president and chief medical officer. Dr. Stamler brings to XenoPort over 15 years of clinical development experience, most recently as the chief scientific officer and head of drug development for Prestwick Pharmaceuticals, Inc.
